Specifically testing EBV+ NS versus GoNL controls revealed that the KIR haplotype B subgroup protects against the development of this cHL subgroup (49% vs. 67%, p = 0.01) (Figure 2C). This evidence concerns the gene KIR3DL1 and classic Hodgkin lymphoma.